Antiplatelet agents in stroke prevention. combination therapy: present and future

Area of Science:

• Cardiovascular Medicine
• Hematology
• Pharmacology

Background:

• Platelets are key in arterial thrombosis, promoting clotting, vasoconstriction, and inflammation, exacerbated by turbulent blood flow.
• Aspirin, a classic antiplatelet agent, provides moderate stroke risk reduction but is less effective than for coronary artery occlusion.
• Aspirin's limitations stem from inhibiting only thromboxane A(2) and not addressing platelet adhesion or other activation pathways.

Purpose of the Study:

• To explore the efficacy of novel antiplatelet agents and combination therapies in preventing stroke.
• To evaluate agents targeting ADP receptors, glycoprotein IIb/IIIa complex, and platelet-dependent thrombin generation.
• To assess the role of soluble recombinant CD39 (an ecto-ADPase) in stroke protection via ADP/ATP metabolism.

Main Methods:

• Review of clinical trials testing combination antiplatelet agents like aspirin/dipyridamole and aspirin/clopidogrel.
• Examination of animal models demonstrating stroke protection with soluble recombinant CD39.
• Analysis of mechanisms underlying synergistic antiplatelet effects and potential risks.

Main Results:

• Combination antiplatelet therapies show promise for enhanced stroke prevention due to synergistic interactions across different pathways.
• Soluble recombinant CD39 demonstrated protective effects against stroke in preclinical animal models.
• Targeting multiple platelet activation pathways offers greater therapeutic potential than single-agent therapy.

Conclusions:

• Combination antiplatelet strategies are likely more effective for stroke prevention than monotherapy.
• Increased bleeding risk, including intracranial and gastrointestinal, necessitates careful risk-benefit assessment in clinical trials.
• Close monitoring of elderly patients in large trials is essential to understand the safety profile of combined antiplatelet treatments.